MNKD - Company ID 0000899460
MANNKIND CORP trades as MNKD and has a market capitalization of $1.29 B, making it the #2473 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $348.97M, up 22.2% from the prior year and net income of $5.86M. This page tracks MANNKIND CORP through 1,648 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-10
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years MANNKIND CORP's revenue grew from $174.76M to $348.97M, a compound annual growth rate of 8.0%. Net profit margin compressed from 71.9% to 1.7% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval | MannKind Corporation
MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes | MannKind Corporation
MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems | MannKind Corporation
MannKind Reports First Quarter 2026 Financial Results and Provides Business Update | MannKind Corporation
MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026 | MannKind Corporation
The largest companies sharing MANNKIND CORP's SEC industry classification (pharmaceutical preparations).
MANNKIND CORP (MNKD) has a market capitalization of $1.29 B as of 2026-07-10, ranking #2473 among US-listed companies.
MANNKIND CORP reported revenue of $348.97M for fiscal year 2025, an increase of 22.2% year over year.
Yes. MANNKIND CORP reported net income of $5.86M in its latest fiscal year.